drugset / Trial / NCT00628758

A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma

NCT00628758

Phase 3 Completed 430 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.

Timeline

Start
2005-12
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Background Symbicort Unknown 4.5 ug Inhaled
Background Symbicort Unknown 160 ug Inhaled
Background Astmerol Unknown
Background Combivent® Unknown
Background Fluticasone propionate Other / unclassified
Background Formoterol Other / unclassified
Background Salbulin Unknown
Background Salbutamol Unknown
Background Salbutamol Sustained Release Unknown
Background Salbutol Unknown
Background Symbicort Unknown
Background Terbutaline Small molecule
Background Vent-o-sal Unknown
Background Ventofor Unknown
Background salmeterol xinafoate Unknown

Indications